Literature DB >> 28225168

Correlations between Epstein-Barr virus and acute leukemia.

Hongzai Guan1, Hongxia Miao1, Na Ma2, Wei Lu1, Bing Luo3.   

Abstract

Infection with Epstein-Barr virus (EBV) may be correlated to the onset of acute leukemia (AL). Studies were performed to investigate the relationship between EBV infection and immunophenotyping of acute lymphoblastic leukemia (ALL) and chromosome aberrations. Additionally, the effects of EBV on clinical prognosis were described. Fluorescence quantitative polymerase chain reaction (FQ-PCR) was used to detect EBV-DNA copy numbers from bone marrow in 110 cases of patients with ALL, 75 cases of patients with acute myeloid leukemia (AML), and 37 cases of hematologically healthy control subjects. EBV-DNA copies were found in 64 of 185 (34.6%) patients with AL and 2 of 37 healthy control subjects (P < 0.001). The EBV infection rate of ALL patients, AML patients, and healthy controls was 40.9% (45/110), 25.3% (19/75), and 5.4% (2/37), respectively. The positive rate of EBV in the ALL and AML groups was higher than in healthy subjects (P < 0.05). EBV-DNA copies were found in 1 of 12 (8.3%) T-ALLs and 44 of 98 (44.9%) B-ALLs, the positive rate of EBV in B-ALLs increased significantly compared to the rate of T-ALLs (P < 0.05). Chromosome karyotype analysis showed that EBV infection rates in B-ALL, T-ALL, and AML patients with chromosome abnormalities were 46.3% (25/54), 33.3% (1/3), and 30% (9/30), respectively. There was no statistical significance between chromosome abnormality and EBV infection (P > 0.05). In addition, EBV+ -ALLs had higher relapse and mortality rates than that of EBV- -ALLs. Together, we conclude that EBV infection may be correlated with the incidence of AL, and the infection rate of EBV in B-ALL was higher than that of T-ALL. EBV-positive patients showed an unfavorable prognosis.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  Epstein-Barr virus; FQ-PCR; acute leukemia; chromosome; karyotyping

Mesh:

Substances:

Year:  2017        PMID: 28225168     DOI: 10.1002/jmv.24797

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  5 in total

1.  IGH rearrangement in myeloid neoplasms.

Authors:  Amy W Xiao; Yuyan Jia; Linda B Baughn; Kathryn E Pearce; Beth A Pitel; Jon C Aster; Paola Dal Cin; Sheng Xiao
Journal:  Haematologica       Date:  2020-03-12       Impact factor: 9.941

Review 2.  Cytomegalovirus and Epstein-Barr Infections: Prevalence and Impact on Patients with Hematological Diseases.

Authors:  Jean de Melo Silva; Renato Pinheiro-Silva; Anamika Dhyani; Gemilson Soares Pontes
Journal:  Biomed Res Int       Date:  2020-10-24       Impact factor: 3.411

3.  Circulating microbial content in myeloid malignancy patients is associated with disease subtypes and patient outcomes.

Authors:  Jakob Woerner; Yidi Huang; Stephan Hutter; Carmelo Gurnari; Jesús María Hernández Sánchez; Janet Wang; Yimin Huang; Daniel Schnabel; Michael Aaby; Wanying Xu; Vedant Thorat; Dongxu Jiang; Babal K Jha; Mehmet Koyuturk; Jaroslaw P Maciejewski; Torsten Haferlach; Thomas LaFramboise
Journal:  Nat Commun       Date:  2022-02-24       Impact factor: 17.694

4.  MicroRNAs in Leukemias: A Clinically Annotated Compendium.

Authors:  Aleksander Turk; George A Calin; Tanja Kunej
Journal:  Int J Mol Sci       Date:  2022-03-23       Impact factor: 5.923

5.  Effects of Lifestyle and Environmental Factors on the Risk of Acute Myeloid Leukemia: Result of a Hospital-based Case-Control Study.

Authors:  Masumeh Maleki Behzad; Mohammad Abbasi; Iman Oliaei; Somayeh Ghorbani Gholiabad; Hassan Rafieemehr
Journal:  J Res Health Sci       Date:  2021-08-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.